Literature DB >> 22048463

Abnormal activity of the MAPK- and cAMP-associated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia.

Adam J Funk1, Robert E McCullumsmith, Vahram Haroutunian, James H Meador-Woodruff.   

Abstract

Recent evidence suggests that schizophrenia may result from alterations of integration of signaling mediated by multiple neurotransmitter systems. Abnormalities of associated intracellular signaling pathways may contribute to the pathophysiology of schizophrenia. Proteins and phospho-proteins comprising mitogen activated protein kinase (MAPK) and 3'-5'-cyclic adenosine monophosphate (cAMP)-associated signaling pathways may be abnormally expressed in the anterior cingulate (ACC) and dorsolateral prefrontal cortex (DLPFC) in schizophrenia. Using western blot analysis we examined proteins of the MAPK- and cAMP-associated pathways in these two brain regions. Postmortem samples were used from a well-characterized collection of elderly patients with schizophrenia (ACC=36, DLPFC=35) and a comparison (ACC=33, DLPFC=31) group. Near-infrared intensity of IR-dye labeled secondary antisera bound to targeted proteins of the MAPK- and cAMP-associated signaling pathways was measured using LiCor Odyssey imaging system. We found decreased expression of Rap2, JNK1, JNK2, PSD-95, and decreased phosphorylation of JNK1/2 at T183/Y185 and PSD-95 at S295 in the ACC in schizophrenia. In the DLPFC, we found increased expression of Rack1, Fyn, Cdk5, and increased phosphorylation of PSD-95 at S295 and NR2B at Y1336. MAPK- and cAMP-associated molecules constitute ubiquitous intracellular signaling pathways that integrate extracellular stimuli, modify receptor expression and function, and regulate cell survival and neuroplasticity. These data suggest abnormal activity of the MAPK- and cAMP-associated pathways in frontal cortical areas in schizophrenia. These alterations may underlie the hypothesized hypoglutamatergic function in this illness. Together with previous findings, these data suggest that abnormalities of intracellular signaling pathways may contribute to the pathophysiology of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22048463      PMCID: PMC3280643          DOI: 10.1038/npp.2011.267

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  112 in total

Review 1.  Neurobiology of schizophrenia.

Authors:  Christopher A Ross; Russell L Margolis; Sarah A J Reading; Mikhail Pletnikov; Joseph T Coyle
Journal:  Neuron       Date:  2006-10-05       Impact factor: 17.173

Review 2.  Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations.

Authors:  David A Lewis; Bita Moghaddam
Journal:  Arch Neurol       Date:  2006-10

Review 3.  NMDA receptors and schizophrenia.

Authors:  Lars V Kristiansen; Ibone Huerta; Monica Beneyto; James H Meador-Woodruff
Journal:  Curr Opin Pharmacol       Date:  2006-11-09       Impact factor: 5.547

4.  AMPA receptor subunit and splice variant expression in the DLPFC of schizophrenic subjects and rhesus monkeys chronically administered antipsychotic drugs.

Authors:  J A O'Connor; E C Muly; S E Arnold; S E Hemby
Journal:  Schizophr Res       Date:  2006-12-01       Impact factor: 4.939

5.  Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia.

Authors:  L V Kristiansen; M Beneyto; V Haroutunian; J H Meador-Woodruff
Journal:  Mol Psychiatry       Date:  2006-05-16       Impact factor: 15.992

6.  Dual role of CaMKII-dependent SAP97 phosphorylation in mediating trafficking and insertion of NMDA receptor subunit NR2A.

Authors:  D Mauceri; F Gardoni; E Marcello; M Di Luca
Journal:  J Neurochem       Date:  2006-11-29       Impact factor: 5.372

7.  Calcium-calmodulin-dependent protein kinase II phosphorylation modulates PSD-95 binding to NMDA receptors.

Authors:  Fabrizio Gardoni; Federica Polli; Flaminio Cattabeni; Monica Di Luca
Journal:  Eur J Neurosci       Date:  2006-11       Impact factor: 3.386

8.  Association of PSD-95 with ErbB4 facilitates neuregulin signaling in cerebellar granule neurons in culture.

Authors:  Fang Xie; Mallika Padival; Ruth E Siegel
Journal:  J Neurochem       Date:  2006-10-27       Impact factor: 5.372

9.  Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons.

Authors:  Anton Ivanov; Christophe Pellegrino; Sylvain Rama; Iryna Dumalska; Yuriy Salyha; Yehezkel Ben-Ari; Igor Medina
Journal:  J Physiol       Date:  2006-05-01       Impact factor: 5.182

Review 10.  Deciphering the disease process of schizophrenia: the contribution of cortical GABA neurons.

Authors:  David A Lewis; Takanori Hashimoto
Journal:  Int Rev Neurobiol       Date:  2007       Impact factor: 3.230

View more
  56 in total

1.  Increased G protein-coupled receptor kinase (GRK) expression in the anterior cingulate cortex in schizophrenia.

Authors:  Adam J Funk; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2014-08-19       Impact factor: 4.939

2.  MicroRNA-382 expression is elevated in the olfactory neuroepithelium of schizophrenia patients.

Authors:  Eyal Mor; Shin-Ichi Kano; Carlo Colantuoni; Akira Sawa; Ruth Navon; Noam Shomron
Journal:  Neurobiol Dis       Date:  2013-03-29       Impact factor: 5.996

Review 3.  Crosstalk between insulin and Toll-like receptor signaling pathways in the central nervous system.

Authors:  Fatemeh Hemmati; Rasoul Ghasemi; Norlinah Mohamed Ibrahim; Leila Dargahi; Zahurin Mohamed; Azman Ali Raymond; Abolhassan Ahmadiani
Journal:  Mol Neurobiol       Date:  2014-01-25       Impact factor: 5.590

4.  Altered serine/threonine kinase activity in schizophrenia.

Authors:  Jennifer L McGuire; John H Hammond; Stefani D Yates; Dongquan Chen; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Brain Res       Date:  2014-04-26       Impact factor: 3.252

5.  Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder.

Authors:  Glenn T Konopaske; Nicholas Lange; Joseph T Coyle; Francine M Benes
Journal:  JAMA Psychiatry       Date:  2014-12-01       Impact factor: 21.596

Review 6.  Mitochondrial Oxidative Phosphorylation System (OXPHOS) Deficits in Schizophrenia: Possible Interactions with Cellular Processes.

Authors:  Oded Bergman; Dorit Ben-Shachar
Journal:  Can J Psychiatry       Date:  2016-08       Impact factor: 4.356

Review 7.  Mapping the Consequences of Impaired Synaptic Plasticity in Schizophrenia through Development: An Integrative Model for Diverse Clinical Features.

Authors:  Jennifer K Forsyth; David A Lewis
Journal:  Trends Cogn Sci       Date:  2017-07-25       Impact factor: 20.229

8.  The schizophrenia risk gene MIR137 acts as a hippocampal gene network node orchestrating the expression of genes relevant to nervous system development and function.

Authors:  Nikkie F M Olde Loohuis; Nael Nadif Kasri; Jeffrey C Glennon; Hans van Bokhoven; Sébastien S Hébert; Barry B Kaplan; Gerard J M Martens; Armaz Aschrafi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2016-02-27       Impact factor: 5.067

Review 9.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

10.  Exome sequences of multiplex, multigenerational families reveal schizophrenia risk loci with potential implications for neurocognitive performance.

Authors:  Mark Z Kos; Melanie A Carless; Juan Peralta; Joanne E Curran; Ellen E Quillen; Marcio Almeida; August Blackburn; Lucy Blondell; David R Roalf; Michael F Pogue-Geile; Ruben C Gur; Harald H H Göring; Vishwajit L Nimgaonkar; Raquel E Gur; Laura Almasy
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-09-13       Impact factor: 3.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.